Have a feature idea you'd love to see implemented?
Let us know!
AGIO Agios Pharmaceuticals Inc
Price (delayed)
$46.94
Market cap
$2.67B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.5
Enterprise value
$2.65B
Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In
Highlights
Agios Pharmaceuticals's gross profit has surged by 59% YoY and by 6% QoQ
The revenue has surged by 55% year-on-year and by 6% since the previous quarter
AGIO's net income has shrunk by 74% YoY and by 3.5% QoQ
Agios Pharmaceuticals's EPS has shrunk by 71% YoY and by 2.8% QoQ
Key stats
What are the main financial stats of AGIO
Market
Valuations
Earnings
Shares outstanding
56.89M
Market cap
$2.67B
Enterprise value
$2.65B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.03
Price to sales (P/S)
85.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
84.67
Revenue
$31.31M
EBIT
-$364.93M
EBITDA
-$347.85M
Free cash flow
-$306.27M
Per share
Balance sheet
Liquidity
EPS
-$6.5
Free cash flow per share
-$5.39
Book value per share
$11.63
Revenue per share
$0.55
TBVPS
$13.61
Total assets
$773.06M
Total liabilities
$112.55M
Debt
$64.62M
Equity
$660.51M
Working capital
$569.49M
Debt to equity
0.1
Current ratio
10.09
Quick ratio
9.16
Net debt/EBITDA
0.06
Margins
Efficiency
Dividend
EBITDA margin
-1,111.1%
Gross margin
89.3%
Net margin
-1,165.7%
Operating margin
-1,293.9%
Return on assets
-40.9%
Return on equity
-47.1%
Return on invested capital
-44.9%
Return on capital employed
-51.4%
Return on sales
-1,165.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AGIO stock price
How has the Agios Pharmaceuticals stock price performed over time
Intraday
0.23%
1 week
5.89%
1 month
5.65%
1 year
130.21%
YTD
110.78%
QTD
5.65%
Financial performance
How have Agios Pharmaceuticals's revenue and profit performed over time
Revenue
$31.31M
Gross profit
$27.97M
Operating income
-$405.06M
Net income
-$364.93M
Gross margin
89.3%
Net margin
-1,165.7%
AGIO's net income has shrunk by 74% YoY and by 3.5% QoQ
Agios Pharmaceuticals's operating income has plunged by 67% YoY and by 3.1% from the previous quarter
Agios Pharmaceuticals's gross profit has surged by 59% YoY and by 6% QoQ
The revenue has surged by 55% year-on-year and by 6% since the previous quarter
Growth
What is Agios Pharmaceuticals's growth rate over time
Valuation
What is Agios Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.03
P/S
85.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
84.67
Agios Pharmaceuticals's EPS has shrunk by 71% YoY and by 2.8% QoQ
The P/B is 75% above the last 4 quarters average of 2.3 and 49% above the 5-year quarterly average of 2.7
Agios Pharmaceuticals's equity has decreased by 31% YoY and by 11% QoQ
The revenue has surged by 55% year-on-year and by 6% since the previous quarter
AGIO's P/S is 43% above its last 4 quarters average of 59.5
Efficiency
How efficient is Agios Pharmaceuticals business performance
AGIO's return on equity has dropped by 133% year-on-year and by 14% since the previous quarter
The company's return on invested capital has shrunk by 131% YoY and by 14% QoQ
The ROA has plunged by 127% YoY and by 12% from the previous quarter
Agios Pharmaceuticals's return on sales has decreased by 12% YoY but it has increased by 2.8% QoQ
Dividends
What is AGIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AGIO.
Financial health
How did Agios Pharmaceuticals financials performed over time
The total assets has declined by 29% year-on-year and by 9% since the previous quarter
The quick ratio is down by 28% year-on-year and by 21% since the previous quarter
The debt is 90% smaller than the equity
Agios Pharmaceuticals's equity has decreased by 31% YoY and by 11% QoQ
The debt to equity has increased by 25% YoY and by 11% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.